Trials / Terminated
TerminatedNCT00057382
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 750 (planned)
- Sponsor
- Tularik · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an international, multicenter, randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma (liver cancer). Patients can not have been treated before with chemotherapy and surgery is not recommended for their cancer. A total of 750 subjects will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T138067 intravenous | |
| DRUG | doxorubicin intravenous |
Timeline
- Start date
- 2003-03-01
- First posted
- 2003-04-02
- Last updated
- 2005-06-24
Locations
76 sites across 11 countries: United States, Brazil, China, Poland, Puerto Rico, Russia, Singapore, South Africa, Thailand, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00057382. Inclusion in this directory is not an endorsement.